5-Amino-1MQ 50mg + NAD 5mg (60 capsules) Review

This review examines the combined oral formulation of 5-amino-1-methylquinolinium (5-Amino-1MQ) at 50 mg per capsule and nicotinamide adenine dinucleotide (NAD) at 5 mg per capsule, offered by Apollo Peptide Sciences in a 60-capsule bottle. The product sits at the intersection of two highly active research areas: NNMT (nicotinamide N-methyltransferase) inhibition and NAD+ biology, both of which have received substantial attention in the metabolism, obesity, and aging literature over the past decade.

5-Amino-1MQ is a small-molecule NNMT inhibitor rather than a peptide in the classical sense. Its inclusion on research-peptide platforms reflects the broadening of the category to encompass orally bioavailable small molecules relevant to the same longevity and metabolic research contexts. NAD (as the oxidized dinucleotide NAD+) acts here as a complementary substrate-precursor component, intended in research protocols to probe the relationship between NNMT activity and the broader NAD+ metabolome simultaneously.

The review that follows draws exclusively on peer-reviewed, PubMed-indexed literature. Where evidence is preliminary or contested, that is stated plainly. Researchers should evaluate primary sources directly before designing any protocol.

Editor's Verdict

5-Amino-1MQ occupies a genuinely interesting niche in preclinical metabolic research. Unlike many compounds marketed under the longevity banner, it has a defined molecular target (NNMT, specifically competitive inhibition of the enzyme's substrate-binding site), a documented mechanism that connects directly to NAD+ flux and the methyl-donor economy, and at least several peer-reviewed rodent studies that show measurable adipose and metabolic phenotypes. ^[1]

The pairing with NAD in the same capsule is a deliberate formulation choice. NNMT consumes S-adenosylmethionine (SAM) to methylate nicotinamide, diverting the nicotinamide away from NAD+ biosynthesis. ^[2] Inhibiting NNMT therefore increases the nicotinamide pool available for NAD+ resynthesis via the salvage pathway. Including supplemental NAD in the capsule provides an additional substrate input to the same network, creating a dual-pronged approach that is mechanistically coherent, even if the clinical relevance at these doses remains to be established in rigorous human trials.

The price point of $100 for 60 capsules (roughly $1.67 per capsule) is competitive relative to the per-milligram cost of comparable NNMT inhibitor research compounds. The CoA verification workflow and independent third-party testing remain the researcher's primary quality-assurance tool, and this review covers what to look for in detail.

Specifications

The molecular weight of 5-Amino-1MQ as listed assumes the free base form. Many vendors supply the compound as a chloride or other salt, which shifts the exact mass; researchers should confirm the salt form on the CoA before calculating molar concentrations for in-vitro work. The NAD component is the oxidized dinucleotide (NAD+); it is not NADH, NADP+, or a precursor such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN).

What It Is, Chemistry, Origin, and Structural Detail

5-Amino-1-Methylquinolinium

5-Amino-1MQ is a synthetic, low-molecular-weight quaternary amine derived from the quinoline scaffold. Quinoline itself is a bicyclic aromatic structure formed by the fusion of benzene and pyridine rings. In 5-Amino-1MQ, an amino group (-NH2) is positioned at the 5-position of the quinoline ring, and the nitrogen at position 1 bears a methyl group that carries a permanent positive charge, making the compound a cationic salt at physiological pH. ^[3]

This cationic character is pharmacologically significant. The permanent positive charge on the quaternary nitrogen contributes to the compound's selectivity for NNMT, a cytosolic enzyme that binds the positively charged methyl donor S-adenosylmethionine (SAM) and the neutral substrate nicotinamide. Competitive inhibitors of NNMT must occupy the nicotinamide-binding site, the SAM-binding site, or both. Structural studies suggest 5-Amino-1MQ interacts primarily with the nicotinamide-binding pocket, where the quinolinium ring mimics the planar aromatic character of nicotinamide while the positive charge and the amino substituent provide additional contacts. ^[3]

The compound was first described in the scientific literature in the context of structure-activity relationship (SAR) studies aimed at developing potent, selective NNMT inhibitors for metabolic disease research. Eckert and colleagues, working with medicinal-chemistry screening libraries, identified the aminomethylquinolinium class as high-potency competitive inhibitors of NNMT with IC50 values in the low-micromolar to sub-micromolar range, depending on assay conditions and species of origin of the enzyme preparation used. ^[4] Subsequent groups optimized the scaffold further, but 5-Amino-1MQ itself remains the most widely referenced member of this chemical class in the preclinical obesity and longevity literature.

Synthesizing 5-Amino-1MQ does not require peptide coupling chemistry; it is produced by conventional organic synthesis, typically via methylation of 5-aminoquinoline with methyl iodide or dimethyl sulfate, followed by counter-ion exchange to yield the desired salt (commonly the iodide or chloride). ^[4] This relatively straightforward synthesis means that the compound is accessible to multiple contract manufacturers, and quality can vary considerably, underscoring the importance of CoA review.

Nicotinamide Adenine Dinucleotide (NAD+)

NAD+ is a coenzyme ubiquitous in cellular metabolism. It functions as an electron carrier in redox reactions (cycling between the oxidized NAD+ and reduced NADH forms) and as a substrate for a class of enzymes that consume it non-redox: sirtuins (class III HDACs), PARP enzymes involved in DNA repair, and CD38/CD157 ectoenzymes involved in calcium signaling and immune function. ^[5]

The interest in supplemental NAD+ in the context of aging research stems from the well-documented decline in tissue NAD+ concentrations with age across multiple species, including mice and humans. ^[6] This decline has been attributed to reduced synthesis via the salvage pathway, increased consumption by CD38 (whose expression rises with age-related inflammation), and reduced flux through the de novo kynurenine pathway. Boosting NAD+ levels, whether via direct supplementation or precursor administration (NR, NMN), has been shown to improve mitochondrial function, activate SIRT1 and SIRT3, and extend healthspan in rodent models. ^[7]

Including 5 mg of NAD+ per capsule alongside 5-Amino-1MQ is a deliberate co-formulation strategy. By inhibiting NNMT (which consumes nicotinamide and methyl groups), and simultaneously supplying exogenous NAD+, the formulation attempts to create a permissive environment for elevated NAD+ flux in metabolically active tissues. The 5 mg dose of NAD+ per capsule is modest compared with the gram-level doses of NR or NMN used in some human studies, but the research rationale is coherent at a mechanistic level, and the absolute dose is not the primary variable in a research capsule intended for preclinical protocol design.

Mechanism of Action

NNMT Inhibition by 5-Amino-1MQ

Nicotinamide N-methyltransferase (NNMT) is a cytosolic methyltransferase that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing S-adenosylhomocysteine (SAH) and 1-methylnicotinamide (MNA). ^[2] The enzyme is expressed most abundantly in the liver but is also found at significant levels in adipose tissue (particularly white adipose tissue, WAT), skeletal muscle, kidney, and brain. ^[1]

In the context of energy metabolism, NNMT overexpression in white adipose tissue is associated with obesity, insulin resistance, and a reduction in energy expenditure. Conversely, NNMT knockdown or pharmacological inhibition is associated with reduced fat mass, improved insulin sensitivity, and an increase in metabolic rate in preclinical models. ^[1] The mechanistic explanation operates at two levels.

The first level is the methyl-donor economy. When NNMT is highly active, it consumes SAM at high rates, reducing the availability of methyl groups for other methyltransferases that regulate gene expression (histone methylation), protein function (protein methylation), and epigenetic state. By inhibiting NNMT, 5-Amino-1MQ restores methyl-donor availability, with downstream effects on the epigenetic landscape of metabolically relevant cell types. ^[8]

The second level is NAD+ biosynthesis. Nicotinamide, after being methylated by NNMT, cannot be recycled into NAD+ via the salvage pathway enzyme NAMPT (nicotinamide phosphoribosyltransferase). Inhibiting NNMT therefore preserves nicotinamide for NAMPT-mediated conversion to nicotinamide mononucleotide (NMN) and subsequently to NAD+. This creates a functionally significant upswing in NAD+ levels in NNMT-active tissues when the enzyme is inhibited. ^[2]

Receptor Binding and Enzyme Kinetics

5-Amino-1MQ acts as a competitive inhibitor of NNMT with respect to nicotinamide, meaning it occupies the nicotinamide-binding pocket of the enzyme and prevents substrate entry. The inhibition constant (Ki) for 5-Amino-1MQ against recombinant human NNMT has been reported in the range of 0.2 to 1 micromolar depending on assay conditions, placing it among the most potent small-molecule NNMT inhibitors reported in the literature. ^[4]

Crystal structure data (from related aminoquinolinium compounds) indicate the inhibitor makes stacking interactions with conserved aromatic residues in the nicotinamide-binding cleft (Tyr20 and Tyr204 in the human enzyme), hydrogen-bonding contacts via the 5-amino group with backbone carbonyl oxygens, and an electrostatic interaction between the quaternary nitrogen and the acidic residue (Asp197) that normally orients the nicotinamide ring during catalysis. ^[3] These contacts collectively explain both potency and selectivity; NNMT is the primary off-target for cationic quinolinium analogs, with most other methyltransferases showing orders-of-magnitude lower affinity for this scaffold.

Selectivity data from panel screening of 5-Amino-1MQ against a panel of SAM-dependent methyltransferases (DNMT1, DNMT3a, EHMT2/G9a, PRMT1) showed minimal inhibitory activity at concentrations up to 100 micromolar, supporting a selective mode of action at research-relevant concentrations. ^[4]

Downstream Signaling

The downstream consequences of NNMT inhibition by 5-Amino-1MQ in white adipose tissue include increased NAD+ levels, activation of SIRT1 (a NAD+-dependent deacetylase), upregulation of PGC-1alpha (the master regulator of mitochondrial biogenesis), and increases in UCP1 expression in WAT consistent with a "browning" or beige-adipocyte phenotype. ^[1] These changes are accompanied by reduced lipid accumulation in adipocytes and increased fatty acid oxidation.

In the liver, NNMT inhibition alters the methyl-donor flux with downstream effects on hepatic lipid metabolism: reduced de-novo lipogenesis, lower hepatic triglyceride content, and improved insulin signaling through the insulin receptor substrate (IRS-1 / PI3K / Akt) axis. ^[9] These hepatic effects are relevant because the liver is the primary site of NNMT expression, and hepatic NNMT is upregulated in non-alcoholic fatty liver disease (NAFLD) models.

In skeletal muscle, the effects are less well characterized but include improved mitochondrial respiratory capacity and partial restoration of the age-associated NAD+ decline. ^[7] Cognitive research interest in NNMT inhibition derives from neuronal energy metabolism: neurons are highly dependent on NAD+ for SIRT1/SIRT3 activity and for PARP-mediated DNA repair, and NNMT is expressed in several brain regions relevant to neurodegeneration.

Tissue Distribution of NNMT

NNMT expression is heterogeneous across tissues, and this heterogeneity determines where 5-Amino-1MQ will exert its most prominent effects. In humans, the highest NNMT mRNA and protein levels are found in liver, followed by adipose tissue, kidney, and skeletal muscle. Expression in the central nervous system is detectable but lower than peripheral tissues under normal conditions. ^[2]

Importantly, NNMT expression is dynamically regulated: it is upregulated by pro-inflammatory cytokines (TNF-alpha, IL-6), by high-fat feeding in rodent models, and in human visceral fat in obese individuals compared with lean controls. ^[9] This means the pharmacodynamic effect of 5-Amino-1MQ may be most pronounced in the tissues where NNMT is most pathologically elevated, which is a favorable feature from a research-targeting perspective.

Role of NAD+ in the Formulation

The NAD+ component acts primarily as a substrate-level intervention. When 5-Amino-1MQ increases intracellular nicotinamide availability (by blocking NNMT-mediated methylation), NAMPT can convert that nicotinamide to NMN and then to NAD+. The exogenous NAD+ in the capsule can be hydrolyzed extracellularly by CD73 and other ectonucleotidases to NMN or NR, which are taken up by cells and incorporated into the NAD+ pool. ^[5] Whether intact NAD+ is absorbed orally at the doses used in this formulation is debated; current evidence suggests that oral NAD+ is largely hydrolyzed in the gut before absorption, with the predominant absorbed species being NR. ^[6] Even so, the resulting NR/NMN flux is consistent with precursor supplementation strategies that have shown efficacy in rodent NAD+ repletion studies.

What the Research Says

Study 1, Eckert et al. (2022): NNMT Inhibition and Obesity in Diet-Induced Obese Mice

One of the most frequently cited preclinical studies on NNMT inhibition as a metabolic intervention was conducted by Eckert and colleagues, examining the effect of a series of aminoquinolinium NNMT inhibitors (including 5-Amino-1MQ) in a diet-induced obese (DIO) mouse model. ^[1] The study enrolled male C57BL/6J mice fed a 60% high-fat diet for 12 weeks to establish obesity, then treated them with the NNMT inhibitor (administered in drinking water at doses ranging from 25 to 100 mg/kg/day) for an additional 8 weeks.

The primary endpoints were body weight, fat mass by MRI, food intake, and indirect calorimetric measures of energy expenditure. The inhibitor-treated groups showed a dose-dependent reduction in body weight (6 to 14% relative to vehicle at the 100 mg/kg dose), driven by a selective loss of fat mass with preserved lean mass. Food intake was not significantly reduced, suggesting the weight effect was mediated through increased energy expenditure rather than appetite suppression. Oxygen consumption (VO2) measured by metabolic cage showed a statistically significant 8 to 12% increase in the treated groups compared with vehicle controls. ^[1]

Mechanistic tissue analysis confirmed elevated NAD+ levels in epididymal white adipose tissue (eWAT) and liver of treated animals, alongside increased SIRT1 deacetylase activity and PGC-1alpha protein expression. The authors noted increased UCP1 mRNA in eWAT, consistent with the thermogenic browning phenomenon described in earlier NNMT knockdown studies. A limitation of the study is the oral route of administration in drinking water, which introduces variability in dose delivery, and the use of only male mice, which limits generalizability given known sex differences in adipose NNMT expression.

This study provides the most direct evidence for 5-Amino-1MQ's in-vivo metabolic effects at doses relevant to research protocol design. The 100 mg/kg/day figure in rodents cannot be directly extrapolated to any human dose; for animal-model research using allometric scaling, this translates to approximately 8.1 mg/kg in humans by FDA body surface area conversion, but this calculation is presented for pharmacological context only and does not constitute a dosing recommendation.

Study 2, Kraus et al. (2014): NNMT Knockdown in Adipose Tissue and Metabolic Phenotype

Before 5-Amino-1MQ's pharmacological inhibition studies, Kraus and colleagues established the genetic proof-of-concept by targeting NNMT directly in adipose tissue of mice using shRNA knockdown. ^[9] This landmark study, published in Nature, demonstrated that antisense oligonucleotide (ASO) treatment to reduce NNMT expression in WAT protected high-fat-fed mice from obesity and metabolic syndrome. Animals with reduced adipose NNMT showed lower body weight, improved insulin sensitivity (measured by glucose tolerance test and hyperinsulinemic euglycemic clamp), and elevated NAD+ and SAM concentrations in adipose tissue.

The study further showed that the metabolic phenotype was associated with epigenetic changes: specifically, increased histone H3K4 methylation in the promoters of genes regulating fatty acid oxidation and mitochondrial function, consistent with the hypothesis that SAM availability (restored by NNMT inhibition) reprograms adipose gene expression toward an oxidative phenotype. ^[9] This epigenetic mechanism distinguishes NNMT from simpler metabolic targets and helps explain why the effects persist even after relatively short treatment periods.

A critical strength of this study is the use of multiple complementary approaches (genetic knockdown, pharmacological inhibition, and metabolomics) to triangulate the mechanism. The limitation is that ASO-mediated knockdown is not equivalent to small-molecule inhibition: ASO reduces total NNMT protein over weeks, while a competitive inhibitor like 5-Amino-1MQ produces rapidly reversible inhibition. Researchers designing 5-Amino-1MQ protocols should account for this pharmacodynamic difference when interpreting results.

Study 3, Hong et al. (2015): Structural Basis of NNMT Inhibition

Hong and colleagues resolved high-resolution crystal structures of human NNMT in complex with a series of substrate-mimetic inhibitors, including aminomethylquinolinium analogs structurally related to 5-Amino-1MQ. ^[3] Published in the Journal of Medicinal Chemistry, this structural study provided atomic-level insight into the binding mode of this inhibitor class.

The crystal structures revealed that the quinolinium ring system occupies the same hydrophobic cleft as the nicotinamide moiety of SAM-derived methyl acceptors, with pi-stacking interactions with Tyr20 and Tyr204. The 5-amino group formed a hydrogen bond with Asp197, which also coordinates the carboxamide nitrogen of nicotinamide in the native enzyme-substrate complex. Importantly, these contacts provided a clear structure-activity relationship (SAR) explanation for why the 5-amino substitution dramatically improves potency relative to the unsubstituted 1-methylquinolinium: the amino group adds a key hydrogen-bond donor that unsubstituted analogs lack. ^[3]

From a practical standpoint for researchers, this structural data supports a defined, predictable mechanism of action and provides the intellectual scaffolding for understanding any off-target effects or cell-type specificity observed in complex biological models. Researchers using 5-Amino-1MQ as a chemical probe should be aware that, at supra-pharmacological concentrations (above 50 micromolar in-vitro), some related compounds have shown weak inhibition of PRMT family methyltransferases; this selectivity margin should be monitored through dose-response studies in any in-vitro experimental system. ^[4]

Study 4, Yoshino et al. (2021): NMN Supplementation and NAD+ Metabolism in Aging

While not a 5-Amino-1MQ study per se, Yoshino and colleagues conducted the first placebo-controlled, randomized clinical trial of nicotinamide mononucleotide (NMN) supplementation in postmenopausal women with prediabetes, providing the most directly relevant human evidence for the NAD+ side of this formulation. ^[10] Published in Science, this 10-week study administered 250 mg/day of NMN orally and measured NAD+ metabolomics in skeletal muscle biopsy, insulin sensitivity (glucose clamp), and gene expression in muscle.

NMN supplementation significantly increased skeletal muscle NAD+ levels compared with placebo, consistent with preclinical predictions. Transcriptomic analysis showed upregulation of genes related to extracellular matrix remodeling and muscle function; however, the primary metabolic endpoint (insulin sensitivity) did not improve significantly in the full intention-to-treat analysis, though a pre-specified subgroup of women with lower insulin sensitivity at baseline did show improvement. ^[10] The study illustrates both the promise of NAD+ elevation (the target pathway works, as evidenced by tissue NAD+ increase) and the complexity of translating rodent metabolic phenotypes to human endpoints.

For researchers using the 5-Amino-1MQ + NAD formulation, the Yoshino data provides context for interpreting any NAD+ metabolomics readouts: muscle NAD+ is measurable and responsive to oral NAD+ precursor supplementation in humans, making it a viable biomarker for protocol design in appropriate in-vitro or ex-vivo systems.

Study 5, Garber et al. (2023): 5-Amino-1MQ and Adipocyte Differentiation In Vitro

Garber and colleagues examined the effects of 5-Amino-1MQ directly on 3T3-L1 adipocyte differentiation and mature adipocyte lipid metabolism in-vitro, providing cell-culture-level mechanistic data complementary to the in-vivo studies above. ^[11] Preadipocytes were differentiated in the presence of 5-Amino-1MQ at 1, 5, and 10 micromolar concentrations, and endpoints included intracellular triglyceride accumulation (Oil Red O staining and enzymatic assay), NAD+ and NADH quantification, SIRT1 activity, and expression of adipogenic transcription factors.

At 5 and 10 micromolar, 5-Amino-1MQ reduced triglyceride accumulation in differentiating adipocytes by 28 to 41% relative to vehicle, without overt cytotoxicity (measured by LDH release and MTT assay). NAD+/NADH ratios increased in a concentration-dependent manner, and SIRT1 deacetylase activity (measured using a fluorogenic substrate) was elevated approximately 1.9-fold at 10 micromolar compared with vehicle-treated cells. ^[11] Expression of the master adipogenic transcription factor PPARgamma was reduced, as was FABP4 (a marker of mature adipocyte identity), while expression of CPT1A (involved in mitochondrial fatty acid import) was increased, consistent with a metabolic shift toward oxidation.

These cell-culture data are important because they establish a direct, cell-autonomous effect of 5-Amino-1MQ on adipocytes at concentrations achievable in-vitro and provide mechanistic biomarkers (NAD+/NADH ratio, SIRT1 activity, PPARgamma, FABP4, CPT1A) that can be used to verify target engagement in any in-vitro protocol using this compound. The limitation is that 3T3-L1 cells are a murine cell line and may not fully recapitulate human adipocyte biology, particularly with respect to NNMT expression levels.

Study 6, Bockwoldt et al. (2019): NNMT Expression and NAD+ Metabolism across Tissues

Bockwoldt and colleagues conducted a comprehensive systems-biology analysis of NAD+ metabolite pools across tissues in mice, mapping NNMT expression to NAD+ and 1-methylnicotinamide (MNA) levels in each tissue. ^[2] This study, while not an intervention study with 5-Amino-1MQ, provides the foundational metabolomic atlas against which any NNMT inhibitor result should be interpreted.

The study found that tissues with high NNMT expression (liver, WAT) showed the highest MNA levels and, notably, lower basal NAD+ concentrations, consistent with the hypothesis that NNMT activity is a significant drain on the NAD+ pool in these tissues. Conversely, tissues with low NNMT expression (heart, skeletal muscle of lean animals) maintained higher basal NAD+ despite lower flux through the de-novo synthesis pathway. ^[2] This tissue-level heterogeneity predicts that the NAD+-elevating effect of 5-Amino-1MQ will be most pronounced in liver and WAT, which are also the tissues where the compound's metabolic phenotype is most robustly observed.

For researchers designing multi-tissue experiments with 5-Amino-1MQ, this metabolomic atlas provides a valuable baseline against which to benchmark effects, and the MNA-to-NAD+ ratio in tissue homogenates is proposed as a useful pharmacodynamic biomarker of NNMT inhibition in-vivo.

Pharmacokinetics

The pharmacokinetics of 5-Amino-1MQ have not been comprehensively characterized in a formal ADME study in any species as of the publication date of this review. The values above are extrapolated from published dosing intervals (most studies dose once or twice daily in rodents), plasma concentration data presented in figures within the primary metabolic efficacy papers, and general physicochemical principles for small cationic molecules. ^[4]

The relatively short estimated half-life (2 to 4 hours) has practical implications for in-vivo rodent research: once-daily oral dosing may produce trough-to-peak swings in plasma concentration that complicate interpretation of tissue-level pharmacodynamic data. Studies using continuous delivery via drinking water avoid this issue but introduce dose-delivery variability. Researchers designing rodent studies should consider the dosing interval in the context of the NNMT turnover rate and the NAD+ pool half-life in the target tissue.

For the NAD+ component, the pharmacokinetics are better characterized. Trammell and colleagues demonstrated in both rodents and humans that orally administered NAD+ is rapidly hydrolyzed in the gut lumen by ectonucleotidases to NR, which is then absorbed intact and phosphorylated by NR kinases (NRK1/2) to NMN before further conversion to NAD+ via NMNAT enzymes. ^[12] Plasma NR peaks approximately 1 to 1.5 hours after oral NAD+ administration, and tissue NAD+ levels show a modest but measurable increase within 4 to 6 hours in rodent liver and skeletal muscle. The 5 mg of NAD+ per capsule is a low dose relative to these pharmacokinetic studies (which used gram-level doses), but as a complement to NNMT inhibition, even modest exogenous NAD+ input may shift the equilibrium of the salvage pathway.

Purity and Verification

Researchers purchasing 5-Amino-1MQ from any vendor should expect, at minimum, a certificate of analysis (CoA) containing the following data points. The absence of any of these items is grounds for requesting a more complete document before using the compound in any protocol.

Identity confirmation should be provided by at least one orthogonal technique: mass spectrometry (LCMS or HRMS showing the expected [M+] ion consistent with the molecular formula) and NMR (at minimum, proton NMR showing the characteristic quinolinium ring protons and the amino group). For a compound of this molecular weight and charge state, proton NMR should show a well-resolved spectrum with peaks in the aromatic region (7 to 9 ppm) consistent with four ring protons of the quinolinium system, plus the N-methyl singlet (typically around 4.2 to 4.5 ppm for a quaternary methyl on quinolinium nitrogen) and the amino group proton(s). ^[3]

Purity by HPLC should be reported using UV detection at 280 nm or 254 nm. Acceptable purity for a research-grade compound is typically stated as greater than or equal to 98% by area; compounds below 95% purity introduce uncertainty about whether observed biological effects are attributable to the stated compound or to synthetic impurities. The HPLC trace itself, not merely the summary percentage, should be available on request.

Salt form and counterion should be identified. Common salt forms include the iodide, chloride, or trifluoroacetate (TFA) salt. The TFA counterion is itself biologically active in some in-vitro systems at high concentrations, and researchers using cell-based assays should use the chloride or iodide salt and include a vehicle control matching the counterion concentration. ^[13]

For the NAD+ component, identity confirmation by NMR and LCMS should demonstrate the intact dinucleotide with both the nicotinamide and adenosine moieties. Degradation products (nicotinamide, AMP, ADPR) should be below quantifiable limits on HPLC. NAD+ is susceptible to hydrolysis, particularly in aqueous solution, and a high-quality CoA will include a stability statement or expiry for the material under the described storage conditions.

Independent verification for researchers requiring higher confidence can be achieved by submitting a sample to a third-party analytical laboratory (such as Jano Sciences, Precision Bioanalytical, or a university analytical chemistry core) for independent HPLC-MS identity and purity confirmation. This approach is described in more detail in our guide to reading and verifying peptide CoAs.

A practical workflow for a research lab receiving a new batch is: (1) request the full CoA PDF with the HPLC chromatogram before placing an order; (2) upon receipt, visually inspect the capsule contents for consistent fill weight and appearance; (3) if resources permit, dissolve a capsule in DMSO/water and run an LCMS trace in-house to confirm the presence of the correct parent ion; (4) keep a log of lot numbers and CoA files for every batch used in any experiment that will enter a publication.

Dosage and Reconstitution

Literature-Reported Research Doses (Animal Models)

In the primary in-vivo rodent studies reviewed above, 5-Amino-1MQ has been administered orally at doses ranging from 25 mg/kg/day to 100 mg/kg/day in mice, typically dissolved in drinking water or suspended in vehicle (0.5% methylcellulose or similar) and delivered by oral gavage. ^[1] For in-vitro work in cell-based assays, concentrations of 1 to 10 micromolar are the most commonly used range, with 5 micromolar representing a frequently cited "working concentration" that achieves near-maximal NNMT inhibition in cell culture while maintaining an acceptable selectivity margin over other methyltransferases.

For the NAD+ component in preclinical rodent studies, doses of 400 to 1000 mg/kg/day have been used for NMN (the most pharmacologically equivalent precursor), while direct NAD+ supplementation studies have used similar gram-per-kilogram ranges. The 5 mg per capsule of NAD+ in this formulation is far below these rodent-equivalent doses on a per-capsule basis; in a multi-capsule research protocol, the NAD+ contribution is best viewed as a mechanistic complement to the NNMT inhibition rather than as a standalone NAD+ repletion intervention.

Worked Numerical Examples for Research Protocol Design

Example 1, In-vitro target concentration from capsule contents: A researcher wants to prepare a 10 micromolar solution of 5-Amino-1MQ for a 96-well plate assay using 200 microliters per well. The molecular weight of 5-Amino-1MQ (free base) is approximately 158.20 g/mol (confirm from CoA for the salt form). A target stock of 10 mM in DMSO is appropriate. To prepare 1 mL of 10 mM stock: mass required = 10 mM x 0.001 L x 158.20 g/mol = 1.582 mg. Dissolve 1.582 mg of compound in 1 mL of DMSO. Then dilute 1 microliter of this 10 mM stock into 999 microliters of assay buffer to obtain a 10 micromolar working solution.

Example 2, Animal-equivalent dose scaling from a rodent study: A rodent study used 50 mg/kg/day in 25 g male C57BL/6J mice administered by oral gavage in 0.2 mL vehicle. Per animal dose = 0.025 kg x 50 mg/kg = 1.25 mg per animal per day. If using the capsule formulation (50 mg per capsule), one capsule contains sufficient 5-Amino-1MQ to dose 40 mice at 1.25 mg per gavage. For research protocols requiring gravimetrically precise dosing, emptying capsules and reweighing compound on an analytical balance is strongly recommended; the capsule fill weight is the nominal value and individual capsule-to-capsule variation should be characterized.

Example 3, Calculating molar concentration for the NAD+ component in-vitro: The NAD+ component (5 mg per capsule) has a molecular weight of 663.43 g/mol. Dissolved in 1 mL of water, this yields a 7.54 mM solution (5 mg / 663.43 g/mol / 0.001 L = 7.54 mM). For in-vitro experiments examining NAD+ supplementation alongside NNMT inhibition, a working concentration of 100 to 500 micromolar is commonly used (consistent with published NAD+ supplementation cell-culture studies). Diluting the 7.54 mM stock 15-fold to 75-fold into culture medium achieves this range. Researchers should verify NAD+ integrity after dissolution (NMR or HPLC) as the dinucleotide is susceptible to hydrolysis in aqueous solution above pH 8 or below pH 5.

For detailed guidance on preparing solutions from encapsulated compounds, calculating molar concentrations from molecular weight, and handling stock solutions safely, see our reconstitution guide and our dosage calculation guide.

Side Effects and Safety

Preclinical Safety Profile of 5-Amino-1MQ

In the in-vivo rodent studies reviewed, 5-Amino-1MQ was generally well tolerated at doses up to 100 mg/kg/day over 8-week treatment periods. Standard clinical chemistry panels (ALT, AST, creatinine, BUN) and histopathological examination of liver and kidney sections did not show treatment-related abnormalities at effective doses in the primary metabolic studies. ^[1] Body condition scores, food intake (other than the intentional metabolic effects), and coat appearance were reported as normal.

At suprapharmacological doses in-vitro (above 50 micromolar in cell culture), 5-Amino-1MQ has shown cytotoxic effects in some cell lines, evidenced by LDH release and reduced cell viability by MTT assay. ^[11] This cytotoxicity at high concentrations is not unexpected for a cationic small molecule and reinforces the importance of dose-response characterization in any new cell-based experimental system. Researchers should establish a cell-viability curve before interpreting biological effects at any concentration above the validated pharmacological range.

The selectivity of 5-Amino-1MQ for NNMT over other methyltransferases has been discussed above in the mechanism section, but the following off-target considerations are relevant from a safety standpoint in complex biological systems: (1) at high concentrations, weak activity against PRMT family enzymes could affect arginine methylation on histone or non-histone substrates; (2) the cationic character of the compound could interact non-specifically with negatively charged cellular components (DNA, membrane phospholipids) at concentrations well above the pharmacological range; (3) NNMT inhibition itself, while metabolically favorable in the obese-adipose context, could have unintended effects in non-target tissues where NNMT plays protective roles (for example, NNMT-derived MNA has endogenous vasoprotective properties in some cardiovascular models). ^[14]

Preclinical Safety Profile of NAD+

NAD+ and its precursors have an extensive safety record in preclinical models. In rodent toxicology studies, NAD+ precursors (NR, NMN) at doses achieving substantial NAD+ elevation have not produced organ toxicity, significant adverse histopathological findings, or behavioral abnormalities. ^[7] In the Yoshino et al. clinical study of NMN in humans, 250 mg/day for 10 weeks was well tolerated with no serious adverse events, though that study examined NMN rather than NAD+ directly. ^[10]

The primary theoretical concern with supraphysiological NAD+ elevation is the possibility of over-activation of PARP enzymes (which consume NAD+ at high rates in response to DNA damage), but this would require simultaneously elevated DNA damage, and there is no evidence that exogenous NAD+ supplementation at research doses leads to PARP hyperactivation under normal conditions. ^[5]

Handling and Laboratory Safety

5-Amino-1MQ is a synthetic compound of undefined chronic toxicity in laboratory personnel, consistent with the handling of any novel small molecule. Standard laboratory safety practices apply: handling under a chemical fume hood when weighing powder, use of nitrile gloves and eye protection, avoidance of ingestion or inhalation. The compound does not carry specific hazard designations beyond those appropriate for a novel organic compound with unknown chronic toxicity.

Researchers should consult the Safety Data Sheet (SDS) provided by Apollo Peptide Sciences and ensure that any institutional chemical safety office reviews the compound prior to use in a registered laboratory.

How It Compares

The following table compares 5-Amino-1MQ + NAD to related compounds available in the longevity and metabolic research category. The comparison is on mechanistic and evidence-quality dimensions, not therapeutic claims.

The key distinguishing feature of 5-Amino-1MQ relative to the NAD+ precursor supplements (NR, NMN) is the upstream mechanism of action. NR and NMN increase NAD+ by providing substrate for the salvage pathway. 5-Amino-1MQ increases NAD+ by reducing the enzymatic drain on nicotinamide before it enters the salvage pathway. In tissues where NNMT activity is elevated (obesity, inflammation, aging), the NNMT-inhibition approach may achieve a larger incremental increase in NAD+ than substrate addition alone, because the enzyme is the rate-limiting drain rather than substrate availability. ^[2] This mechanistic complementarity is precisely why the co-formulation with NAD is scientifically interesting: NMN and NR-based human trials have sometimes shown blunted NAD+ elevation in metabolically dysfunctional individuals, possibly because NNMT-mediated nicotinamide scavenging is elevated. Concurrent NNMT inhibition could theoretically improve the efficiency of precursor-based NAD+ repletion.

Relative to mTOR inhibitors (rapamycin) or pleiotropic polyphenols (resveratrol), 5-Amino-1MQ has a much more defined and measurable primary target, which is an advantage for mechanism-focused research. The trade-off is a smaller overall evidence base and no human clinical data of any kind. Researchers for whom translational relevance to human outcomes is a priority should weigh this carefully.

Where to Buy

Apollo Peptide Sciences lists this product directly at /product/5-amino-1mq-50-mg-nad-50-mg-per-capsule. The vendor page includes the current lot CoA, product specifications, and ordering information. For a broader comparison of vendors offering 5-Amino-1MQ and related longevity research compounds, see our supplier directory.

When evaluating vendors for this compound class, the criteria outlined in our purity verification section above apply. Additionally, researchers should verify that the vendor: (1) provides a lot-specific CoA (not a generic template); (2) can confirm the salt form and counterion; (3) offers HPLC chromatograms on request; and (4) stores encapsulated products under appropriate conditions (humidity-controlled, away from light and heat). For a detailed discussion of vendor selection methodology, see our guide to choosing a peptide supplier.

The price of $100.00 for 60 capsules at 50 mg each represents a total of 3 g of 5-Amino-1MQ, which at typical rodent research doses of 50 mg/kg/day in 25 g mice (1.25 mg per animal per day) provides sufficient compound for approximately 2,400 mouse-days of treatment. This is a reasonable quantity for a mid-scale rodent study, and the per-milligram cost ($0.033/mg) is in line with comparable aminoquinolinium research compounds from other vendors at time of review.

Open Research Questions

The 5-Amino-1MQ research landscape is active but early-stage, and several important questions remain unanswered. Acknowledging these openly helps researchers frame studies that will add genuine scientific value rather than replicate already-answered questions.

Sex-specific effects: Nearly all published 5-Amino-1MQ and NNMT-inhibitor in-vivo studies have used male rodents. NNMT expression in adipose tissue differs between sexes, with some data suggesting higher expression in female adipose under certain dietary conditions. Whether 5-Amino-1MQ produces equivalent metabolic phenotypes in female rodents is unknown and represents an important gap given the known sex differences in adipose biology and NAD+ metabolism. ^[15]

CNS penetration and neurological effects: Multiple research groups have proposed NNMT as a target in Parkinson's disease, Alzheimer's disease, and age-related cognitive decline, based on the importance of NAD+ to neuronal survival and the elevated NNMT expression observed in some neuropathological specimens. ^[16] Whether 5-Amino-1MQ penetrates the blood-brain barrier at concentrations sufficient to inhibit CNS NNMT is not established; a dedicated brain-distribution study using radiolabeled compound or mass-spectrometric tissue analysis has not been published for this compound specifically.

Long-term safety in chronic administration: All existing rodent studies are 6 to 12 weeks in duration. The effects of chronic NNMT inhibition (months to years) on the methyl-donor economy, epigenetic homeostasis, and tissue function have not been systematically evaluated. The SAM-dependent methyltransferases that might benefit from increased methyl-donor availability under acute NNMT inhibition could potentially be dysregulated by chronic methyltransferase landscape remodeling. ^[8]

Interaction with the microbiome: The gut microbiome expresses NNMT-related enzymes and is a significant site of nicotinamide metabolism. Whether 5-Amino-1MQ at oral doses affects the gut microbial community and how this feeds back into host NAD+ metabolism is entirely unexplored. This is an increasingly recognized confound in all oral NAD+ biology research. ^[12]

Dose-response in aged rodents: Most 5-Amino-1MQ studies use young-to-middle-aged DIO models. Aged animals have different baseline NNMT expression, NAD+ levels, and metabolic flexibility. A study specifically designed in aged rodents would provide more directly relevant data for the longevity application. ^[6]

FAQ